Rationale for active vitamin D analog therapy in senile osteoporosis

PTH is a potent endogenous stimulator of bone resorption, and PTH secretion increases with age (i.e., secondary hyperparathyroidism). Accordingly, secondary hyperparathyroidism may contribute to the pathogenesis of senile osteoporosis. We postulate that there is a subgroup of elderly subjects who ha...

Full description

Saved in:
Bibliographic Details
Published in:Calcified tissue international 1997-01, Vol.60 (1), p.100-105
Main Authors: Akesson, K, Lau, K H, Baylink, D J
Format: Article
Language:English
Subjects:
Aged
Aging
Calcitriol - therapeutic use
Female
Humans
Osteoporosis - drug therapy
Osteoporosis - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523
cites cdi_FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523
container_end_page 105
container_issue 1
container_start_page 100
container_title Calcified tissue international
container_volume 60
creator Akesson, K
Lau, K H
Baylink, D J
description PTH is a potent endogenous stimulator of bone resorption, and PTH secretion increases with age (i.e., secondary hyperparathyroidism). Accordingly, secondary hyperparathyroidism may contribute to the pathogenesis of senile osteoporosis. We postulate that there is a subgroup of elderly subjects who have elevated serum PTH because of 1,25(OH)^sub 2^D^sub 3^ deficiency/resistance or both. We believe that with appropriate vitamin D therapy (vitamin D, 1,25(OH)^sub 2^D^sub 3^ or 1α(OH)D^sub 3^) and adequate calcium, much of the problem associated with secondary hyperparathyroidism seen in the senile osteoporotic patient can be effectively treated.[PUBLICATION ABSTRACT]
doi_str_mv 10.1007/s002239900195
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78818273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2709424231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523</originalsourceid><addsrcrecordid>eNqF0U1LxDAQBuAgyrquHj0KBcFbdZI0SXMU1y9YEETBW0nbqWZpmzVpF_bfG9lF0IungczDMG-GkFMKlxRAXQUAxrjWAFSLPTKlGWcp5EztkylQRVMt1dshOQphGUkmpZyQiQYOWa6nZP5sBut602LSOJ-YarBrTNZ2MJ3tk3liYsu9J8MHerPaJPEtYG-jdmFAt3LeBRuOyUFj2oAnuzojr3e3LzcP6eLp_vHmepFWPFNDWkPZSJHljNUShWpAGEnjRohlXWHJtIIKdSxMybKiZcM5q1WuBBUlF4LxGbnYzl159zliGIrOhgrb1vToxlCoPKcxOP8XUqGZkFJFeP4HLt3oY-ZogGVSq4zlUaVbVcW4wWNTrLztjN9EVHwfofh1hOjPdlPHssP6R-9-nX8BcvB_6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1024697428</pqid></control><display><type>article</type><title>Rationale for active vitamin D analog therapy in senile osteoporosis</title><source>Springer Nature</source><creator>Akesson, K ; Lau, K H ; Baylink, D J</creator><creatorcontrib>Akesson, K ; Lau, K H ; Baylink, D J</creatorcontrib><description>PTH is a potent endogenous stimulator of bone resorption, and PTH secretion increases with age (i.e., secondary hyperparathyroidism). Accordingly, secondary hyperparathyroidism may contribute to the pathogenesis of senile osteoporosis. We postulate that there is a subgroup of elderly subjects who have elevated serum PTH because of 1,25(OH)^sub 2^D^sub 3^ deficiency/resistance or both. We believe that with appropriate vitamin D therapy (vitamin D, 1,25(OH)^sub 2^D^sub 3^ or 1α(OH)D^sub 3^) and adequate calcium, much of the problem associated with secondary hyperparathyroidism seen in the senile osteoporotic patient can be effectively treated.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 0171-967X</identifier><identifier>EISSN: 1432-0827</identifier><identifier>DOI: 10.1007/s002239900195</identifier><identifier>PMID: 9030489</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Aged ; Aging ; Calcitriol - therapeutic use ; Female ; Humans ; Osteoporosis - drug therapy ; Osteoporosis - physiopathology</subject><ispartof>Calcified tissue international, 1997-01, Vol.60 (1), p.100-105</ispartof><rights>Springer-Verlag 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523</citedby><cites>FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9030489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akesson, K</creatorcontrib><creatorcontrib>Lau, K H</creatorcontrib><creatorcontrib>Baylink, D J</creatorcontrib><title>Rationale for active vitamin D analog therapy in senile osteoporosis</title><title>Calcified tissue international</title><addtitle>Calcif Tissue Int</addtitle><description>PTH is a potent endogenous stimulator of bone resorption, and PTH secretion increases with age (i.e., secondary hyperparathyroidism). Accordingly, secondary hyperparathyroidism may contribute to the pathogenesis of senile osteoporosis. We postulate that there is a subgroup of elderly subjects who have elevated serum PTH because of 1,25(OH)^sub 2^D^sub 3^ deficiency/resistance or both. We believe that with appropriate vitamin D therapy (vitamin D, 1,25(OH)^sub 2^D^sub 3^ or 1α(OH)D^sub 3^) and adequate calcium, much of the problem associated with secondary hyperparathyroidism seen in the senile osteoporotic patient can be effectively treated.[PUBLICATION ABSTRACT]</description><subject>Aged</subject><subject>Aging</subject><subject>Calcitriol - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - physiopathology</subject><issn>0171-967X</issn><issn>1432-0827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNqF0U1LxDAQBuAgyrquHj0KBcFbdZI0SXMU1y9YEETBW0nbqWZpmzVpF_bfG9lF0IungczDMG-GkFMKlxRAXQUAxrjWAFSLPTKlGWcp5EztkylQRVMt1dshOQphGUkmpZyQiQYOWa6nZP5sBut602LSOJ-YarBrTNZ2MJ3tk3liYsu9J8MHerPaJPEtYG-jdmFAt3LeBRuOyUFj2oAnuzojr3e3LzcP6eLp_vHmepFWPFNDWkPZSJHljNUShWpAGEnjRohlXWHJtIIKdSxMybKiZcM5q1WuBBUlF4LxGbnYzl159zliGIrOhgrb1vToxlCoPKcxOP8XUqGZkFJFeP4HLt3oY-ZogGVSq4zlUaVbVcW4wWNTrLztjN9EVHwfofh1hOjPdlPHssP6R-9-nX8BcvB_6g</recordid><startdate>199701</startdate><enddate>199701</enddate><creator>Akesson, K</creator><creator>Lau, K H</creator><creator>Baylink, D J</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>199701</creationdate><title>Rationale for active vitamin D analog therapy in senile osteoporosis</title><author>Akesson, K ; Lau, K H ; Baylink, D J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Aged</topic><topic>Aging</topic><topic>Calcitriol - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akesson, K</creatorcontrib><creatorcontrib>Lau, K H</creatorcontrib><creatorcontrib>Baylink, D J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Calcified tissue international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akesson, K</au><au>Lau, K H</au><au>Baylink, D J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rationale for active vitamin D analog therapy in senile osteoporosis</atitle><jtitle>Calcified tissue international</jtitle><addtitle>Calcif Tissue Int</addtitle><date>1997-01</date><risdate>1997</risdate><volume>60</volume><issue>1</issue><spage>100</spage><epage>105</epage><pages>100-105</pages><issn>0171-967X</issn><eissn>1432-0827</eissn><abstract>PTH is a potent endogenous stimulator of bone resorption, and PTH secretion increases with age (i.e., secondary hyperparathyroidism). Accordingly, secondary hyperparathyroidism may contribute to the pathogenesis of senile osteoporosis. We postulate that there is a subgroup of elderly subjects who have elevated serum PTH because of 1,25(OH)^sub 2^D^sub 3^ deficiency/resistance or both. We believe that with appropriate vitamin D therapy (vitamin D, 1,25(OH)^sub 2^D^sub 3^ or 1α(OH)D^sub 3^) and adequate calcium, much of the problem associated with secondary hyperparathyroidism seen in the senile osteoporotic patient can be effectively treated.[PUBLICATION ABSTRACT]</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>9030489</pmid><doi>10.1007/s002239900195</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0171-967X
ispartof Calcified tissue international, 1997-01, Vol.60 (1), p.100-105
issn 0171-967X
1432-0827
language eng
recordid cdi_proquest_miscellaneous_78818273
source Springer Nature
subjects Aged
Aging
Calcitriol - therapeutic use
Female
Humans
Osteoporosis - drug therapy
Osteoporosis - physiopathology
title Rationale for active vitamin D analog therapy in senile osteoporosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T17%3A10%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rationale%20for%20active%20vitamin%20D%20analog%20therapy%20in%20senile%20osteoporosis&rft.jtitle=Calcified%20tissue%20international&rft.au=Akesson,%20K&rft.date=1997-01&rft.volume=60&rft.issue=1&rft.spage=100&rft.epage=105&rft.pages=100-105&rft.issn=0171-967X&rft.eissn=1432-0827&rft_id=info:doi/10.1007/s002239900195&rft_dat=%3Cproquest_cross%3E2709424231%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-d0bf654822d6e57f05a61146eebdceb2970ce9297276bc1bf332d787515b35523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1024697428&rft_id=info:pmid/9030489&rfr_iscdi=true